INTRODUCTION {#s1}
============

Pancreatic adenocarcinoma is the fourth most lethal malignancy in the United States, with 39,590 deaths expected in 2014. \[[@R1]\] It is one of the few malignancies where incidence approximates prevalence, as the disease is almost uniformly fatal, often within one year (Table [1](#T1){ref-type="table"}). \[[@R2], [@R3]\] For patients who present with localized disease that can be surgically removed, median survival is 22.8 months due to the high-likelihood of recurrence. \[[@R4]\] Most patients present with metastatic disease, and treatment options are limited to chemotherapy. Median survival is about five to seven months with single-agent gemcitabine, or 8.5--11 months with more intense regimens such as gemcitabine/nab-paclitaxel and fluorouracil (5-FU)/irinotecan/oxaliplatin (FOLFIRINOX). \[[@R5]--[@R7]\]

###### Current treatment strategies for newly-diagnosed pancreatic cancer

  Clinical Scenario                                   Treatment                                                                                MedianOS   1-year Survival   Comment                                                 Reference(s)
  --------------------------------------------------- ---------------------------------------------------------------------------------------- ---------- ----------------- ------------------------------------------------------- -------------------------------
  Resectable                                          Surgical Resection; 6 Months Adjuvant Therapy with Gemcitabine and 5-FU Chemoradiation   20.5 Mos   73%               Pancreas head lesions only                              Regine et al, 2011 \[[@R55]\]
  Surgical Resection; 6 Months Adjuvant Gemcitabine   22.8 Mos                                                                                 72%                          Oettle et al, 2007, 2013 \[[@R4], [@R56]\]              
  Locally-Advanced                                    3 Months Chemotherapy; 5-FU Chemoradiation                                               15.0 Mos   65%               Patients that developed mets post-chemo were excluded   Huguet at al, 2007 \[[@R57]\]
  Metastatic                                          FOLFIRINOX                                                                               11.1 Mos   48%                                                                       Conroy et al, 2011 \[[@R7]\]
  Gemcitabine + Nab-paclitaxel                        8.5 Mos                                                                                  35%                          Von Hoff et al, 2013 \[[@R6]\]                          
  Gemcitabine                                         5.7 Mos                                                                                  18%                          Burris et al, 1997 \[[@R5]\]                            

Recent survival gains in the treatment of pancreatic cancer have resulted from new combinations of conventional, non-targeted chemotherapies, such as FOLFIRINOX. \[[@R7]\] Only one targeted agent -- erlotinib, a small-molecule tyrosine-kinase inhibitor of EGFR -- has been shown to improve overall survival (OS) when combined with gemcitabine. \[[@R8]\] This improvement was a modest 11 days compared to gemcitabine alone. Other targeted agents, such as bevacizumab, cetuximab, and sorefenib, did not improve overall survival in combination with gemcitabine. \[[@R9]--[@R11]\] Trials with these agents were open to all patients with pancreatic cancer, and there were no screening criteria to select patients most likely to respond to the targeted agents.

Outside the field of pancreatic cancer, significant advances in oncology therapy have emerged by identifying and intervening upon "actionable" aberrations. Advanced melanoma, which traditionally held a grave prognosis, has undergone a renaissance in treatment options. For the approximately 40% of patients that harbor a V600E *BRAF* mutation, vemurafenib produces a response rate of 48%. \[[@R12], [@R13]\] Dabrafenib, another BRAF inhibitor, and trametinib, a MEK inhibitor, have also substantially improved outcomes in *BRAF*-mutant patients. \[[@R14], [@R15]\] In advanced non-small cell lung cancer (NSCLC), median survival with traditional platinum-doublet chemotherapy is eight to nine months. \[[@R16]\] Targeting the EML4-ALK fusion product (\~5% incidence) with crizotinib, a small-molecule kinase inhibitor, is associated with a survival of about 20 months. \[[@R17]\] Even erlotinib, whose effect is modest in pancreatic cancer, can improve first-line progression-free survival (PFS) in patients with *EGFR*-mutations (about 8--30% depending upon ethnicity) from 4.6 to 13 months. \[[@R18]--[@R20]\] Further, a meta-analysis of the NSCLC literature showed responses of 49% when targeted treatments were matched to the appropriate subgroup of patients, but only 9.7% when unselected populations were treated. \[[@R21]\]

In this regard, a review of pancreas tumor specimens within the Catalogue of Somatic Mutations in Cancer (COSMIC) database reveals that most pancreatic cancers harbor somatic mutations (Table [2](#T2){ref-type="table"}), with the five most frequent aberrations being *KRAS*, *TP53*, *CDKN2A*, *SMAD4*, and *ARID1A*. \[[@R22], [@R23]\] If specific "actionable" mutations can drive marked improvements in survival in melanoma and NSCLC, similar opportunities might reasonably be expected in pancreatic cancer. Herein we review the molecular landscape in pancreatic cancer and provide an overview of the status of current clinical trials in the field.

###### Most common mutated genes of pancreatic ductal carcinoma in COSMIC database[\*](#tfn-001){ref-type="table-fn"}

  Mutated Gene                                     Frequency   Wild-Type Gene Function[\*\*](#tfn-002){ref-type="table-fn"}   
  ------------------------------------------------ ----------- -------------------------------------------------------------- ----------------------------------------------------------
  *KRAS*                                           71%         4573                                                           GTPase mediating cell signaling
  *TP53*                                           49%         796                                                            Tumor suppressor
  *CDKN2A*                                         22%         950                                                            Tumor suppressor
  *SMAD4*                                          20%         680                                                            Signal transduction protein
  *ARID1A*                                         6%          343                                                            Chromatin remodeling
  *MLL3*                                           4%          292                                                            Histone methylation
  *PIK3CA*                                         3%          377                                                            Protein kinase mediating cell signaling
  *MAP2K4*                                         3%          294                                                            Protein kinase mediating cell signaling
  *ATM*                                            3%          190                                                            Protein kinase mediating cell cycle checkpoint signaling
  *ACVR1B*                                         3%          226                                                            Growth factor receptor kinase
  *BRAF*                                           2%          528                                                            Protein kinase mediating cell signaling
  *APC*                                            2%          267                                                            Tumor suppressor
  *SF3B1*                                          2%          206                                                            RNA splicing
  *STK11/LKB1*                                     2%          314                                                            Tumor suppressor
  *FBXW7*                                          2%          242                                                            Component of SCF-complex mediating ubiquitination
  *SMARCA4*                                        1%          291                                                            Transcriptional regulation
  *ARID2*                                          2%          189                                                            Transcriptional regulation
  *CREBBP*                                         2%          190                                                            Histone acetylation
  *RNF43*                                          2%          197                                                            Ubiquitin ligase
  *EP300*                                          1%          201                                                            Histone acetylation
  *ERBB2*[\*\*\*](#tfn-003){ref-type="table-fn"}   0.4%        256                                                            Receptor tyrosine kinase

Accessed December 1, 2014 (<http://www.sanger.ac.uk/cosmic>) \[[@R22]\].

National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine, Gene database (<http://www.ncbi.nlm.nih.gov/gene>).

In addition to mutation, HER2 may be overexpressed or amplified in \~10 to 30% of patients \[[@R58]--[@R60]\].

KRAS {#s1_1}
----

Seventy-one percent of pancreatic cancer specimens in the COSMIC database harbor *KRAS* mutations. \[[@R22]\] KRAS is a key protein in multiple signaling pathways. When bound to guanosine triphosphate (GTP), it mediates cell survival and differentiation. Common *KRAS* mutations hinder its ability to hydrolyze GTP, leaving it constitutively active. \[[@R24]\] *KRAS* mutations are common in pancreatic duct lesions and are thought to play an early role in oncogenesis. \[[@R25]\] Thus, blocking targets downstream of KRAS is of clinical interest.

One key target downstream of KRAS is MEK, which functions as a protein kinase. Multiple MEK inhibitors are in development, and some have shown promise (Table [3](#T3){ref-type="table"}). Selumetinib, a small-molecule MEK inhibitor, was randomized against single-agent capecitabine as a second-line treatment for advanced pancreatic cancer. Though there was no difference in overall survival, two of 38 (5.2%) patients in the selumetinib arm achieved a partial response (PR) \[[@R26]\]. Trametinib has also shown some activity. In a treatment-refractory phase I population, two of 26 patients (8%) achieved PR \[[@R27]\]. However, in a randomized phase II trial with trametinib given in combination with gemcitabine versus gemcitabine alone, response rate was 22% (but included one complete remission) as compared to 18%; survival was 8.4 versus 6.7 months (p, not significant). \[[@R28]\] The fact that some patients respond to MEK inhibitors alone is of interest, though combinations of MEK inhibitors with gemcitabine do not substantially increase the response rate. Whether or not MEK inhibitors in combination with other regimens such as FOLFIRINOX might be beneficial merits further study.

###### Clinical trials with MEK1/2 inhibitors in metastatic pancreatic cancer

  Agent                                 Line of Therapy   Phase of Study        Partial Remission (PR)                         Comment                                       Reference
  ------------------------------------- ----------------- --------------------- ---------------------------------------------- --------------------------------------------- ---------------------------------
  Trametinib + Gemcitabine              1^st^ Line        Randomized Phase II   17/77 (22%);(includes one complete remission   PR 14/77 (18%) in placebo + gemcitabine arm   Infante et al, 2014 \[[@R28]\]
  Trametinib + Gemcitabine              Mixed             Phase Ib              3/11 (27%)                                     Two patients had received prior therapy       Infante et al, 2013 \[[@R61]\]
  Trametinib                            Refractory        Phase I               2/26 (8%)                                                                                    Infante et al, 2012 \[[@R27]\]
  Selumetinib vs. Capecitabine          2nd Line          Phase II              2/38 (5%)                                                                                    Bodoky et al, 2011 \[[@R26]\]
  XL-518 / GDC-0973 + GDC-0941 (PI3K)   Refractory        Phase Ib              1 PR                                           Patient with PR had a *BRAF* mutation         LoRusso et al, 2012 \[[@R62]\]
  CI-1040                               1st Line          Phase II              0/15 (0%)                                                                                    Rinehart et al, 2004 \[[@R63]\]
  CI-1040                               Refractory        Phase I               1/6 (17%)                                                                                    LoRusso et al, 2005 \[[@R64]\]

KRAS {#s1_2}
----

Forty-nine percent of pancreatic cancers in the COSMIC database demonstrate *TP53* mutations. \[[@R22]\] p53 is key tumor suppressor, and when in an inactivated state, enables cancerous cells to avoid apoptosis. Wee-1 inhibitors such as MK1775 target aberrant p53 by blocking cell cycle checkpoint regulation and increasing susceptibility to cytotoxic chemotherapy. \[[@R29]\] In addition, retrospective analysis by Said et al \[[@R30]\] suggested that tumors with aberrant p53 may be more sensitive to bevacizumab. Patients with aberrant p53 had a median PFS of 11 months while the median PFS in those with wild-type p53 was 5.0 months. On multivariate analysis, the interaction between p53 mutation status and bevacizumab therapy was statistically significant \[HR 0.15, 95% CI 0.05--0.44, *p* \< 0.001\]. \[[@R30]\]

Of additional clinical interest is re-activating p53 in wild-type patients. MDM2, an inhibitor of p53, is overexpressed in many cancers. \[[@R31]\] MDM2--p53 interaction prompts p53 degradation and blocks its tumor suppressor function. \[[@R31]\] Blocking MDM2 activity may prevent this degradation, thereby enabling p53-induced apoptosis of cancerous cells. \[[@R32]\] A search of [clinicaltrials.gov](http://clinicaltrials.gov) lists multiple MDM2 antagonists currently under early-phase investigation, including RO5045337, RO5503781, and DS-3032b. \[[@R33]\]

KRAS {#s1_3}
----

*CDKN2A* is aberrant in twenty-two percent of patients with pancreatic cancer. \[[@R22]\] It encodes multiple proteins which play roles in tumor suppression. Two transcripts, p16 and p14^ARF^, are frequently abnormal in pancreatic cancer and result in loss of function. p16 inhibits the activity of cyclin-dependent kinases 4/6, thereby playing a regulatory role in the cell cycle by preventing phosphorylation of the tumor suppressor retinoblastoma protein. \[[@R34]\] Loss of p16 results in activation of CDK4/6 and is associated with high-grade pre-malignant pancreatic lesions. \[[@R35]\] Palbociclib, an inhibitor of CDK4/6, has been shown to suppress growth of pancreatic cancer cell lines, though with upregulation of genes associated with metastasis. \[[@R36]\] p14^ARF^ is an inhibitor of MDM2 and stabilizes retinoblastoma protein by interfering with MDM2-mediated degradation. \[[@R37]\] Theoretically, either CDK4/6 or MDM2 inhibitors might be active in patients with loss of *CDKN2A* function.

KRAS {#s1_4}
----

SMAD4 is a co-factor that facilitates gene transcription and tumor suppression through the TGF-beta signaling pathway. *SMAD4* mutations are present in twenty percent of pancreatic cancers and have been associated a poorer prognosis and increased metastases. \[[@R22], [@R38], [@R39]\] Inactivation of *SMAD4* may enable TGF-beta signaling, which is usually suppressive, to promote cancer growth. \[[@R40], [@R41]\] To our knowledge, the role of TGF-beta inhibitors in patients with SMAD4 mutations has not been investigated.

KRAS {#s1_5}
----

*ARID1a* mutations are present in six percent of pancreatic cancers. \[[@R22]\] ARID1a plays a role in chromatin remodeling, is thought to have tumor suppressor function, and binds p53. \[[@R42]\] It also modulates signaling through the PI3K/AKT/mTOR axis. \[[@R43]\] Whether or not mutations in *ARID1a* can be targeted by using PIK3CA, AKT or mTOR inhibitors is currently unknown.

Other potentially actionable mutations {#s1_6}
--------------------------------------

BRCA2 is a potent tumor suppressor and plays a key role in DNA repair. Murphy et al demonstrated that 5/29 patients (17%) with a strong family history of pancreatic cancer harbored *BRCA2* mutations. \[[@R44]\] PALB2, which binds BRCA2, also plays a role in DNA repair. *PALB2* mutations were reported in 3/96 patients (3.1%) with familial pancreatic cancer. \[[@R45]\]

In theory, patients with *BRCA2* or *PALB2* mutations should be more sensitive to DNA-damaging agents. Two case reports illustrate this point (Table [4](#T4){ref-type="table"}). Villarroel et al reported a 61-year-old man with metastatic pancreatic cancer in the setting of a *PALB2* mutation. \[[@R46]\] He was initially treated with gemcitabine chemotherapy (nucleoside analogue) with no response, but then received mitomycin C chemotherapy (DNA crosslinker) and achieved a partial response that lasted twenty-two months. A 49-year-old woman with advanced pancreatic cancer in the setting of *BRCA2* mutation who was treated with mitomycin C and capecitabine after progressing through two previous regimens also achieved a partial response. \[[@R47]\] Mitomycin C was discontinued after six months due to toxicity. Patients with *BRCA2* mutations may also be sensitive to PARP inhibitors. Response has been seen in a variety of other tumors, including breast, prostate, and ovarian cancer harboring *BRCA2* aberrations. \[[@R48]\]

###### Case reports of novel therapies in advanced pancreatic cancer

  Aberration              Histology              Agent                        Line   Outcome            Rationale for Agent                                                                                     Reference
  ----------------------- ---------------------- ---------------------------- ------ ------------------ ------------------------------------------------------------------------------------------------------- -----------------------------------
  *PALB2* Mutation        Adenocarcinoma         Mitomycin C                  2nd    Partial Response   Patient\'s tumor xenograft demonstrated sensitivity to mitomycin C                                      Villarroel et al, 2011 \[[@R46]\]
  *BRCA2* Mutation        Adenocarcinoma         Mitomycin C + Capecitabine   3rd    Partial Response   Pre-clinical data with mitomycin C in *BRCA2* cell lines and prior published responses to mitomycin C   Chalasani et al, 2008 \[[@R47]\]
  *STK11/LKB1* Mutation   Acinar Cell Carcioma   Everolimus                   1st    Partial Response   Loss of mTOR inhibition with *STK11/LKB1* mutation                                                      Klumpen et al, 2011 \[[@R50]\]

Abberations in *STK11/LKB1* and *FBXW7* are also potential targets. LKB1 acts through AMPK to inhibit mTOR, which regulates cell growth. \[[@R49]\] Germline *STK11/LKB1* loss-of function mutations are associated with Peutz-Jeghers Syndrome, which carries an increased risk for pancreatic neoplasms. \[[@R49]\] A case reported by Klumpen at al successfully used the mTOR inhibitor everolimus in a Peutz-Jeghers Syndrome patient with pancreatic cancer to obtain a partial response without additional cytotoxic chemotherapy (Table [4](#T4){ref-type="table"}). \[[@R50]\] FBXW7 plays a role in the ubiquitin-mediated degradation of oncoproteins, and among patients with NSCLC, low *FBXW7* expression is associated with decreased survival and taxane resistance. In NSCLC cell lines with silenced *FBXW7*, taxane sensitivity can be restored when treated with the histone deacetylase inhibitor MS-275. \[[@R51]\]

Other potentially actionable aberrations that can be seen in small, but not insignificant subsets of patients include *PIK3CA* and *BRAF* mutations. These abnormalities occur in 2 to 3% of patients, and can theoretically be targeted by PI3K/AKT/mTOR and BRAF or MEK inhibitors, respectively.

Clinical trials for pancreatic cancer {#s1_7}
-------------------------------------

A search of [clinicaltrials.gov](http://clinicaltrials.gov) for new pancreatic cancer protocols registered during the past three years identified 314 protocols (search criteria: trials registered in database during the period 03/01/2011 to 03/01/2014; pancreatic cancer; drug or biological intervention studies). \[[@R33]\] The 314 protocol summaries were manually reviewed, and protocols containing external radiotherapy, neuroendocrine histology, and local therapy were excluded, as were protocols without the stated outcome of improved OS, PFS, or radiographic/biochemical response, leaving only 116 specific for pancreatic adenocarcinoma systemic therapy. Of these 116 protocols, 10 (8.6%) used selective inclusion criteria to identify a subset of patients based upon laboratory molecular/biomarker data and treat with a cognate therapy that was believed to impact or biologically match the biomarker. Six used tissue biomarkers to assign patients among multiple conventional chemotherapy options, two sought patients with *BRCA* mutations for PARP inhibitors, one required a specific antigen for a corresponding investigational monoclonal antibody, and one sought patients with a specific HLA marker for a vaccine study. These results suggest that there is still a remarkable paucity of trials addressing molecular/biomarker stratification in pancreatic cancer.

CONCLUSIONS {#s2}
===========

The outcome for patients diagnosed with pancreatic cancer is grim, with one year survival of 19% and 4.8% alive at five years. \[[@R52]\] The best therapy to date is FOLFIRINOX, and it improves median survival by four months (from 6.8 to 11.1 months) compared to gemcitabine for metastatic disease. \[[@R7]\] In other tumor types such as *BRAF*-aberrant melanoma, or *EGFR*- or *ALK*-aberrant NSCLC, significant improvements have been achieved by matching targeted agents with patients harboring the cognate molecular abnormality. Several theoretically "actionable" aberrations exist in pancreatic cancer including, but not limited to, *KRAS, CDKN2A, ARID1A, BRCA, PALB2, PIK3CA, BRAF* and so forth. Despite the number of aberrations that can be targeted, relatively few have been addressed in clinical trials of pancreatic cancer, with only about 9% of clinical trials of pancreatic cancer stratified by a biomarker in the last three years. Although an important step in pancreatic cancer, as in *EGFR*- or *ALK*-mutant lung cancer or BRAF-mutant melanoma might include investigation of matched targeted monotherapy, many pancreatic tumors likely contain more than one aberration. If two or more genomic aberrations exist, the role of each might need to be ascertained, and each important driver may need to be targeted (customized combination therapy) in order to prevent or circumvent resistance. \[[@R53], [@R54]\] Taken together, the data suggests that efforts to target biomarker-defined subsets of patients with pancreatic cancer in order to optimize therapy benefit are warranted.
